The President and Plan B
This article was originally published in The Tan Sheet
Executive Summary
President Bush's sentiments about birth control are "directly at odds with FDA's extraordinary refusal to approve OTC sale of emergency contraception products," according to letter to the President sent by the Center for Reproductive Rights July 6. The letter refers to a recent statement by the Bush administration that the President supports the "availability of safe and effective products and services to assist responsible adults in making decisions about preventing or delaying conception." The administration's position on birth control was requested by Members of Congress in July 2005. The reasons for delaying an answer to Barr Labs' Plan B switch application "appear to have nothing to do with the safety or effectiveness of Plan B - the only considerations that are the proper purview of the FDA," CRR maintains. "If the administration indeed supports safe and effective products and services to assist responsible adults...then there is no reason for its failure to support the availability of EC"...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.